Wolters Kluwer, Omnicell Partnership Delivers First Integrated IV Sterile Compounding Solution Covering the Full Quality Spectrum of Pharmacy Workflow and Compliance

BELLEVUE, Wash., Dec. 1, 2017 /PRNewswire/ -- Wolters Kluwer Health today announced a partnership with Omnicell, Inc. (NASDAQ: OMCL) to distribute Omnicell's IVX Workflow system, which integrates with Wolters Kluwer's market-leading Simplifi 797^®. The partnership enables customers to easily acquire and deploy integrated automation and quality tools together to improve accuracy, enhance safety and facilitate compliance with IV compounding best practices.

"Today's healthcare organizations face unprecedented pressure to achieve a higher standard of sterile compounding practice and are seeking a comprehensive approach to quality and compliance," said David A. Del Toro, President and CEO of Clinical Software Solutions at Wolters Kluwer. "We are pleased to integrate Simplifi 797 with Omnicell's next-generation workflow technology and distribute these together as one solution to ensure sterile compounding environments have all the best practice tools and resources needed to meet USP <797> and USP <800> compliance standards, elevate staff competencies and keep patients safe."

Pharmacists use the integrated IVX Workflow system to customize and design risk-based IV workflows for different compounding applications and remain fully compliant with USP <797> and USP <800>. This enhances compounding workflows by equipping pharmacists with integrated barcode scanning, gravimetric or volumetric verifications, advanced image recognition, photo documentation and label printing—all within a single compact package designed for easy placement within laminar airflow hoods or isolators.

"The integration with Simplifi 797 further elevates safety and compliance by providing the expert content needed to align with complex USP guidelines, including risk management and quality assurance practices, comprehensive policies and procedures, staff training and evaluations and robust reporting," said Rob Seim, President of Global Automation and Medication Adherence at Omnicell, Inc. "We are thrilled to have our new IV workflow solution integrated with this market-leading quality management and compliance software."

Wolters Kluwer will demonstrate the integrated IVX Workflow system in Booth #1633 at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, taking place December 2-7 in Orlando. For more information, click here.

About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and the organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

For more information about Wolters Kluwer's solutions and organization, visit www.wolterskluwer.com, follow us on Twitter,Facebook, LinkedIn, and YouTube.

OMCL-G

View original content with multimedia:http://www.prnewswire.com/news-releases/wolters-kluwer-omnicell-partnership-delivers-first-integrated-iv-sterile-compounding-solution-covering-the-full-quality-spectrum-of-pharmacy-workflow-and-compliance-300565499.html

SOURCE Omnicell, Inc.